<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701697</url>
  </required_header>
  <id_info>
    <org_study_id>ART-2019-002</org_study_id>
    <nct_id>NCT04701697</nct_id>
  </id_info>
  <brief_title>Phase Ib of Recombinant Human Albumin Injection</brief_title>
  <official_title>Phase Ib Study of Recombinant Human Albumin Injection for the Treatment of Ascites in Patients With Hepatic Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Multicenter,Open-label, positive-controlled, Multi-dose Phase 1 Study to&#xD;
      Evaluate the Safety, Tolerance,Efficacy, Pharmacokinetics and Immunogenicity of recombinant&#xD;
      human albumin injection in Patients With Hepatic Cirrhosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was to evaluate the safety, tolerability,efficacy, pharmacokinetics and&#xD;
      immunogenicity of recombinant human albumin injection in Patients With Hepatic Cirrhosis. The&#xD;
      study design consists of two phases: Screening and treatment phase(dose increasing&#xD;
      stage).Following the Screening phase, all eligible subjects will be randomized to receive&#xD;
      recombinant human albumin injection or HumanAlbumin, study medication in a 3:1 ratio.Dose&#xD;
      increasing stage (including 3 dose groups with increasing dose, and each group was set with&#xD;
      HumanAlbumin control).The initial dose was 10g. The highest dose group was set at 30g.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Actual">October 25, 2020</completion_date>
  <primary_completion_date type="Actual">September 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major efficacy character: Albumin concentration change</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Albumin concentration change from baseline to Day 14（approximately，After the treatment）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy：Ascites regression rate</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Ascites regression rate from baseline at Day 14（approximately，After the treatment）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy：Ascites resolution time</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Ascites resolution time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy： HRS (hepato-renal syndrom)</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Incidence of HRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy： OHE(overt hepatic encephalopathy)</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Incidence of OHE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy： abdominal circumference</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Change of abdominal circumference from baseline at Day 14（approximately，After the treatment）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy：Weight</measure>
    <time_frame>Day 1-Day 14（approximately，After the treatment）</time_frame>
    <description>Change of Weight from baseline at Day 14（approximately，After the treatment）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters</measure>
    <time_frame>Day 1-Day 29</time_frame>
    <description>Plasma colloidal osmotic pressure change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Day 1-Day 29</time_frame>
    <description>Maximum Plasma Concentration（Cmax）of ALB as Recombinant Human Albumin administration occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Day 1-Day 29</time_frame>
    <description>Time to Maximum Plasma Concentration（Tmax）of ALB as Recombinant Human Albumin administration occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Day 1-Day 29</time_frame>
    <description>Half life (t1/2）as Recombinant Human Albumin administration occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Day 1-Day 29</time_frame>
    <description>Area under the curve(AUC) as Recombinant Human Albumin administration occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 1-Day 29</time_frame>
    <description>Percentage of patients with positive reaction against human albumin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>active comparator：HumanAlbumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received HumanAlbumin 10g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:Recombinant Human Albumin Injection 10g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Recombinant Human Albumin Injection 10g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:Recombinant Human Albumin Injection 20g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Recombinant Human Albumin Injection 20g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:Recombinant Human Albumin Injection 30g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Recombinant Human Albumin Injection 30g/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Albumin Injection</intervention_name>
    <description>Participants will receive Recombinant Human Albumin Injection of intravenous infusion</description>
    <arm_group_label>Experimental:Recombinant Human Albumin Injection 10g</arm_group_label>
    <arm_group_label>Experimental:Recombinant Human Albumin Injection 20g</arm_group_label>
    <arm_group_label>Experimental:Recombinant Human Albumin Injection 30g</arm_group_label>
    <other_name>Intravenous infusion of human albumin injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HumanAlbumin</intervention_name>
    <description>Participants will receive HumanAlbumin of intravenous infusion</description>
    <arm_group_label>active comparator：HumanAlbumin</arm_group_label>
    <other_name>Intravenous infusion of recombinant human albumin injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-75 years of age;&#xD;
&#xD;
          2. No less than 45 kg.&#xD;
&#xD;
          3. Diagnosed with ascites due to cirrhosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to biological products;&#xD;
&#xD;
          2. West-Haven HE ≥ III ;&#xD;
&#xD;
          3. Uncontrolled severe infections;&#xD;
&#xD;
          4. HRS. Serum creatinine (Cr)&gt;2×ULN, or Cr increase&gt;50% during the screening period;&#xD;
&#xD;
          5. Combined with other serious underlying diseases.&#xD;
&#xD;
          6. Organ transplant recipients;&#xD;
&#xD;
          7. Child-bearing females. Pregnancy test positive. Refusing to take contraceptive&#xD;
             measures; (8) Participation in other clinical trials. Using study drugs within three&#xD;
             month; (9) With the following laboratory test abnormality:&#xD;
&#xD;
               1. PLT&lt;30×109/L, HGB&lt;70 g/L;&#xD;
&#xD;
               2. ALT and (or) AST&gt; 5×ULN, TBIL&gt;3×ULN;&#xD;
&#xD;
               3. Prothrombin activity &lt;40%, PT prolonged&gt;5s;&#xD;
&#xD;
               4. LVEF &lt;50%;&#xD;
&#xD;
               5. The 24h urine volume exceeds 1500 mL/day ;&#xD;
&#xD;
        10) Other subjects by investigator's opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junqi Niu, Dr</last_name>
    <role>Study Director</role>
    <affiliation>The first affiliated hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

